Log in

Relevant bibliographies by topics / Psychological aspects of Lymphocytic leukemia

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Reports

Academic literature on the topic 'Psychological aspects of Lymphocytic leukemia'

Author: Grafiati

Published: 4 June 2021

Last updated: 16 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Psychological aspects of Lymphocytic leukemia.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Psychological aspects of Lymphocytic leukemia"

1

Pangalis, Gerassimos A., Theodoros P. Vassilakopoulos, Maria N. Dimopoulou, Marina P. Siakantaris, Flora N. Kontopidou, and Maria K. Angelopoulou. "B-chronic lymphocytic leukemia: practical aspects." Hematological Oncology 20, no. 3 (2002): 103–46. http://dx.doi.org/10.1002/hon.696.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Kay, Neil E., Terry J. Hamblin, Diane F. Jelinek, Gordon W. Dewald, John C. Byrd, Sherif Farag, Margaret Lucas, and Thomas Lin. "Chronic Lymphocytic Leukemia." Hematology 2002, no. 1 (January 1, 2002): 193–213. http://dx.doi.org/10.1182/asheducation-2002.1.193.

Full text

Abstract:

Abstract This update of early stage B-cell chronic lymphocytic leukemia (B-CLL) embraces current information on the diagnosis, biology, and intervention required to more fully develop algorithms for management of this disease. Emphasis on early stage is based on the rapid advancement in our understanding of the disease parameters and our increasing ability to predict for a given early stage patient whether there is a need for more aggressive management. In Section I, Dr. Terry Hamblin addresses the nature of the disease, accurate diagnostic procedures, evidence for an early “preclinical” phase, the use of newer prognostic features to distinguish who will be likely to progress or not, and whether it is best to watch or treat early stage disease. In Section II, Dr. Neil Kay and colleagues address the biologic aspects of the disease and how they may relate to disease progression. Review of the newer insights into gene expression, recurring genetic defects, role of cytokines/autocrine pathways, and the interaction of the CLL B cell with the microenvironment are emphasized. The relationship of these events to both trigger disease progression and as opportunities for future therapeutic intervention even in early stage disease is also considered. In Section III, Dr. John Byrd and colleagues review the historical and now current approaches to management of the previously untreated progressive B-CLL patient. They discuss what decision tree could be used in the initial decision to treat a given patient. The use of single agents versus newer combination approaches such as chemoimmunotherapy are discussed here. In addition, the place of marrow transplant and some of the newer antibodies available for treatment of B-CLL are considered. Finally, a challenge to utilize our growing knowledge of the biology of B-CLL in the early stage B-CLL is proffered.

APA, Harvard, Vancouver, ISO, and other styles

3

García-Muñoz, Ricardo, Verónica Roldan Galiacho, and Luis Llorente. "Immunological aspects in chronic lymphocytic leukemia (CLL) development." Annals of Hematology 91, no. 7 (April 12, 2012): 981–96. http://dx.doi.org/10.1007/s00277-012-1460-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Goyal, Neha G., Kami J. Maddocks, Amy J. Johnson, John C. Byrd, Travis D. Westbrook, and Barbara L. Andersen. "Cancer-Specific Stress and Trajectories of Psychological and Physical Functioning in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia." Annals of Behavioral Medicine 52, no. 4 (February 9, 2018): 287–98. http://dx.doi.org/10.1093/abm/kax004.

Full text

Abstract:

Abstract Background Chronic lymphocytic leukemia is the most prevalent adult leukemia. The disease is incurable with a cycling of treatment and relapse common. Little is known about the psychological and physical functioning of patients with relapsed/refractory chronic lymphocytic leukemia. Cancer-specific stress is an important individual difference variable that predicts psychological and physical outcomes. Purpose To examine cancer-specific stress at treatment initiation as a predictor of psychological and physical functioning trajectories in patients with relapsed/refractory chronic lymphocytic leukemia during the first 5 months of treatment. Methods Patients with relapsed/refractory chronic lymphocytic leukemia (N = 152) enrolled in a phase II clinical trial completed self-report measures at treatment initiation (baseline), 1, 2, and 5 months of treatment. Cancer-specific stress at baseline was examined as a predictor of psychological (cognitive-affective depressive symptoms, negative mood, mental health quality of life) and physical functioning (fatigue interference, sleep problems, physical health quality of life), controlling for demographic and treatment variables. Results Using multilevel modeling, higher baseline cancer-specific stress was related to worse psychological (cognitive-affective depressive symptoms, negative mood, mental health quality of life) and physical functioning (fatigue interference, sleep problems) at baseline and more rapid improvements during the next 5 months. Despite these improvements, higher baseline cancer-specific stress remained associated with poorer 5-month psychological, though not physical, functioning. Conclusions Findings suggest cancer-specific stress at treatment initiation may be a risk factor for poorer psychological functioning during treatment for patients with relapsed/refractory chronic lymphocytic leukemia.

APA, Harvard, Vancouver, ISO, and other styles

5

Rudakova, A. V., and E. A. Stadnik. "Pharmacoeconomic aspects of recurrent / refractory chronic lymphocytic leukemia treatment." Oncohematology 15, no. 1 (April 19, 2020): 73–82. http://dx.doi.org/10.17650/1818-8346-2020-15-1-73-82.

Full text

Abstract:

Background. Currently, treatment of recurrent / refractory chronic lymphocytic leukemia (CLL) involves the appointment of regimens with innovative drugs, which include ibrutinib and a combination of venetoclax and rituximab. Wherein said combination provides continuing over time high frequency eradication of minimal residual disease. Thereby, this regimen can be canceled if patients do not progress after 2 years from therapy start.The objective of the study was to assess the pharmacoeconomic aspects of therapy with venetoclax and rituximab combination in patients with recurrent / refractory CLL compared with ibrutinib monotherapy.Materials and methods. Analysis was performed by a simulation method from a position of the health care system. In accordance with network meta-analysis results of clinical studies in the recurrent / refractory CLL treatment (MURANO for venetoclax + rituximab combination and RESONATE and HELIOS for ibrutinib), which showed the absence of statistically significant differences in progression-free and overall survival between these treatment options, the cost-minimization method was used in the analysis. In the basic version, the model time horizon is 4 years. The price of venetoclax, rituximab and ibrutinib in the calculation corresponded to that registered (for rituximab – the median of the registered prices) with the value-added tax and the weighted average wholesale allowance taking into account the population in Russia.When analyzing the healthcare system budget impact, the time horizon of the study was 4 years. Therapy with combination of venetoclax + rituximab starting from the first year was suggested in 100 % of newly identified recurrent / refractory CLL patients. In the base case, it was estimated that 100 patients would need therapy every year.In the basic version of analysis, the cost of therapy after progression was not taken into account. In sensitivity analysis, an option taking into account therapy cost after progression, suggesting the appointment of venetoclax in the ibrutinib group and ibrutinib in the venetoclax + rituximab group, was also evaluated. In addition, variants with disease progression were additionally evaluated in 15 % of patients per year in the venetoclax therapy group at the end of the 2-year treatment course, as well as with an increase and decrease in the disease progression rate by 15 % in both comparison groups.As part of the sensitivity analysis, an assessment is made of a 15 % decrease and increase in Venetoclax price, a 30 % decrease in Ibrutinib price compared to registered price and the option with a 3-year study time horizon. When analyzing the budget impact, options with an increase in the number of patients annually identified and requiring treatment by 10, 20, 30 and 50 % were evaluated. Clinical and economic analysis was carried out with a discount rate of 3.5 % per year. A budget impact analysis was performed without discounting.Results. According to the results of cost-effectiveness analysis in the basic version, a regimen including venetoclax can reduce costs by 46.3 % compared with ibrutinib (cost for 4 years per patient is 10.422 and 19.413 million rubles, respectively). Therapy with combination of venetoclax + rituximab in 100 newly identified recurrent / refractory CLL patients annually instead of ibrutinib monotherapy will result in a reduction in therapy costs by 29.0 %, or by 1.579 billion rubles for 4 years per 100 patients starting therapy annually. The sensitivity analysis demonstrated the high reliability of the results. Conclusion. The treatment of recurrent / refractory CLL with a combination of venetoclax and rituximab is comparable in clinical efficacy with ibrutinib monotherapy and can significantly reduce the cost of the healthcare system, and therefore increase the availability of innovative therapy for this group of patients.

APA, Harvard, Vancouver, ISO, and other styles

6

Faderl, Stefan, William Wierda, and Michael J. Keating. "New aspects of the treatment of chronic lymphocytic leukemia." Current Hematologic Malignancy Reports 1, no. 4 (December 2006): 251–57. http://dx.doi.org/10.1007/s11899-006-0006-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Carlucci, F., F. Rosi, C. Di Pietro, E. Marinello, M. Pizzichini, and A. Tabucchi. "Purine nucleotide metabolism: specific aspects in chronic lymphocytic leukemia lymphocytes." Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1360, no. 3 (May 1997): 203–10. http://dx.doi.org/10.1016/s0925-4439(96)00077-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Vincent, AM, JC Cawley, and J. Burthem. "Integrin function in chronic lymphocytic leukemia." Blood 87, no. 11 (June 1, 1996): 4780–88. http://dx.doi.org/10.1182/blood.v87.11.4780.bloodjournal87114780.

Full text

Abstract:

Integrins are central to many aspects of the tissue localization of normal and malignant lymphocytes. We examined how integrin function, rather than simple expression, might determine disease behavior in chronic lymphocyte leukemia (CLL). Using fluorescence-activated cell sorting (FACS) and immunoprecipitation, we first established the precise integrin heterodimer expression of a representative group of CLL patients (beta1 consistently present, with variable alpha 3, alpha 4, and alpha 5; alpha 4 beta 7 often expressed; alpha L beta 2 high; alpha V beta 3 absent). Regarding function, we initially examined the ability of CLL cells to interact with endothelium, because such interaction is the initial event determining the entry of CLL lymphocytes into tissues. The abnormal lymphocytes were shown to bind at low levels to unstimulated endothelium via beta 2/intercellular adhesion molecule (ICAM). However, when the endothelium was stimulated, markedly enhanced interaction with endothelium was observed in approximately half the cases; in these patients, the neoplastic population expressed alpha 4 beta 1, which conferred the ability to adhere strongly to stimulated endothelium via the alpha 4 beta 1 ligand, vascular cellular adhesion molecule-1 (VCAM-1). In relation to the migration of CLL cells within tissues, the abnormal lymphocytes showed differential binding to various adhesive proteins; they did not attach to basement membrane components, but displayed variable adhesion to fibronectin (FN). Finally, we examined the role of cell activation in these processes, and showed that activated CLL lymphocyte populations showed an increased capacity to adhere to both endothelium and matrix. Moreover, ex vivo CLL cells showed no capacity to migrate through endothelium/stroma, but were able to do so after cytokine stimulation. These studies show how the constitutive integrin expression/function, the intrinsic activation state of the cell, and the capacity of cytokines to modify integrin-mediated function all combine to determine the different patterns of clinical disease observed in CLL.

APA, Harvard, Vancouver, ISO, and other styles

9

C. Riches, John, and John G. Gribben. "Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic Leukemia." Current Cancer Drug Targets 16, no. 8 (September 2, 2016): 689–700. http://dx.doi.org/10.2174/1568009616666160408145741.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Alzamora, Meritxell Garcia, Markus Schmidli, Urs Hess, Richard Cathomas, and Roger von Moos. "Minimal Change Glomerulonephritis in Chronic Lymphocytic Leukemia: Pathophysiological and Therapeutic Aspects." Oncology Research and Treatment 29, no. 4 (2006): 153–56. http://dx.doi.org/10.1159/000091644.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Psychological aspects of Lymphocytic leukemia"

1

Weiss, David Michael. "Psychological Factors and Vaccine Immunity in Patients with Chronic Lymphocytic Leukemia." The Ohio State University, 2020. http://rave.ohiolink.edu/etdc/view?acc_num=osu1575891774538146.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Morrison, Eleshia JP. "Psychological Distress and Symptom Burden: Vulnerabilities in Chronic Lymphocytic Leukemia Patients." The Ohio State University, 2013. http://rave.ohiolink.edu/etdc/view?acc_num=osu1366305005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Weiss, David M. "Cancer-Specific Stress and Absolute Lymphocyte Count Trajectories in Patients with Chronic Lymphocytic Leukemia." The Ohio State University, 2016. http://rave.ohiolink.edu/etdc/view?acc_num=osu147765209495775.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Strosnider, Deborah Vivian 1958. "AN EXPLORATION OF PERCEPTIONS OF PAIN IN CHILDREN WITH LEUKEMIA." Thesis, The University of Arizona, 1986. http://hdl.handle.net/10150/275484.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Larery, Angela R. D. "Hierarchical neuropsychological functioning in pediatric survivors of acute lymphoblastic leukemia." Thesis, University of North Texas, 2007. https://digital.library.unt.edu/ark:/67531/metadc3949/.

Full text

Abstract:

Acute lymphocytic leukemia (ALL) is one of the most common types of pediatric cancers. Improvements in treatment within the last 20 years have resulted in reduced mortality and a greater focus upon quality of life. Several researchers have documented neuropsychological impairments in children following treatment for ALL; however, there have not been any comparative studies documenting differences in neuropsychological functioning based upon treatment modality despite the documented effects of radiation therapy and combined radiation/chemotherapy upon the developing brain. In addition, past studies have focused on unitary measures, ignoring the hierarchical relationship between basic cognitive functions and more abstract skills. This study examined the neuropsychological functioning of 81 children who were treated for ALL at a metropolitan children's hospital. All children were tested a minimum of two years after the final treatment session and were administered the NEPSY. Results do not support any interactions or main effects with the exception of the age of the child at diagnosis. Children diagnosed prior to the age of 5 showed greater impairments on tasks measuring attention, memory, and visuospatial reasoning in comparison to peers diagnosed after age 6.

APA, Harvard, Vancouver, ISO, and other styles

6

Westbrook, Travis Dexter. "The Relation of Illness Perception to Psychological Distress and Physical Symptom Burden in Relapsed/Refractory Chronic Lymphocytic Leukemia." The Ohio State University, 2014. http://rave.ohiolink.edu/etdc/view?acc_num=osu1416781156.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Luna, Solorzano Maria Isela 1964. "THE "TAKING CARE OF MYSELF" PHENOMENON IN MEXICAN-AMERICAN CHILDREN WITH LEUKEMIA (PEDIATRICS, HISPANIC PATIENTS)." Thesis, The University of Arizona, 1986. http://hdl.handle.net/10150/277226.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Goyal, Neha Godiwala. "The Impact of Cancer-Specific Stress on Psychological, Physical, and Immunological Responses in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia." The Ohio State University, 2015. http://rave.ohiolink.edu/etdc/view?acc_num=osu1437104095.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Tsaguris, Chrysann Angeliki 1952. "Self and nurses' perceptions of adolescent boys with leukemia: An exploration based on the psychology of personal constructs." Thesis, The University of Arizona, 1988. http://hdl.handle.net/10150/276705.

Full text

Abstract:

Literature on psychological aspects of childhood cancer has treated adolescents as a homogeneous group, while revealing little about their individuality. This study's purpose was to systematically explore similarities and differences in adolescent boys with leukemia and to explore nurses' perceptions of the boys. Participants were recruited from a pediatric oncology clinic; the boys were 13, 14, and 18 years old and were selected based on age, active treatment for leukemia, and rapport with the investigator. To elicit constructs used by each boy to interpret feelings, the study employed a variant of psychologist George Kelly's technique for eliciting unique organizing principles (personal constructs) by which Kelly theorized people interpret experience (1955). The boys rated themselves on their personal constructs; their nurses also rated them on the constructs. Results reveal distinctive differences and certain similarities in the boys' personal constructs. Nurses' ratings of each patient differ in varying degrees from his own.

APA, Harvard, Vancouver, ISO, and other styles

10

Begyn, Elizabeth. "The psychosocial functioning in pediatric cancer survivors: The role of neurocognitive abilities." Thesis, University of North Texas, 2007. https://digital.library.unt.edu/ark:/67531/metadc4003/.

Full text

Abstract:

With the increase in survival for children with cancer, part of the focus of current research is aimed towards evaluating how these children are adapting psychosocially. Neurocognitive deficits have been well established. However, there are multiple facets encompassing quality of life, including general mental health, lifestyles and health behaviors, and academic and cognitive functioning. The relationship between neurocognitive and psychosocial functioning has yet to be thoroughly evaluated. The purpose of this study was to investigate the relationship between neurocognitive and psychosocial functioning in survivors of brain tumors and acute lymphoblastic leukemia. Data was collected from existing archival database comprised of patients of the at Cook Children's Medical Center in Texas. The sample consisted of 177 patients between the ages of 3 and 12 who were at least two years post-diagnosis. Measures used included the NEPSY and the Behavioral Assessment for Children. Statistical analyses included a several one-way analysis of variances, an independent samples t-test, a univariate analysis of variance, a hierarchical multiple regression, and odds ratio analyses. Results indicated survivors treated with neurosurgery alone appear to be less at risk for developing behavior problems than other treatment modalities. Also, brain tumor survivors demonstrate more problematic behaviors than survivors of acute lymphoblastic leukemia. Visuospatial functioning, diagnosis, and type of treatment were found to be predictive variables of behavior problems. Attention, and perhaps language, deficits may predispose children to more problems in their behavior. It is concluded that there are other factors affecting behavior in this population that were not accounted for in this analysis. It is recommended for future studies to research the individual clinical scales of the Behavior Assessment System for Children, obtain information from multiple informants, study this relationship longitudinally, and research additional factors that may be influencing the relationship between neurocognitive and psychosocial functioning. This provides evidence of risk factors that should be monitored as the child returns home and to school.

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Psychological aspects of Lymphocytic leukemia"

1

Nyondo, Florence. New every morning. Lusaka: Multimedia Publications, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Secker-Walker, Lorna M. Chromosomes and genes in acute lymphoblastic leukemia. New York: Springer, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Kanō, Tomoko. Mukin byōtō yori ai o komete. Tōkyō: Bungei Shunjū, 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Blankenship, Jayne. In the center of the night: Journey through a bereavement. Toronto: PaperJacks, 1986.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Noe: A father-son song of love, life, illness, and death. Berkeley, Calif: North Atlantic Books, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Livingston, Gordon. Only spring: On mourning the death of my son. [San Francisco, Calif.]: HarperSanFrancisco, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Siegel, Andrea. Snapshots from the heart: A memoir about my dad. New York: Agapanthus Books, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Laslo, Dionne Elise. The relation between child coping, parent coping and psychosocial adjustment in children and adolescents with acute lymphocytic leukemia. 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

CLL family registry update form. [Bethesda, MD: National Cancer Institute, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Ghelani, Karen. Arithmetic processing in adolescents treated for leukemia. 1999.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Psychological aspects of Lymphocytic leukemia"

1

Langerak, Anton W., and Yorick Sandberg. "Chronic Lymphocytic Leukemia." In Molecular Aspects of Hematologic Malignancies, 85–101. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-29467-9_5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Foon, Kenneth A., and Robert Peter Gale. "Interferon Therapy of Chronic Lymphocytic Leukemia and Viral Infections in Leukemia Patients." In Clinical Aspects of Interferons, 141–48. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4613-1737-1_11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Binet, J. L. "New Aspects in the Treatment of Chronic Lymphocytic Leukemia." In Acute Leukemias V, 569–71. Berlin, Heidelberg: Springer Berlin Heidelberg, 1996. http://dx.doi.org/10.1007/978-3-642-78907-6_97.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Yaghmaie, Marjan, Mohammad Ahmadvand, Ali-akbar Nejati Safa, and Hossein Pashaiefar. "Genetic, Hematologic and Psychological Aspects of Leukemia." In Cancer Genetics and Psychotherapy, 667–755. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-64550-6_14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Langerak, Anton W., Richard Rosenquist, Paolo Ghia, Chrysoula Belessi, Kostas Stamatopoulos, and Frederic Davi. "Studies of Rearrangements and Somatic Hypermutation of IGHV Genes in Chronic Lymphocytic Leukemia." In Molecular Aspects of Hematologic Malignancies, 429–42. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-29467-9_26.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Put, N., I. Wlodarska, P. Vandenberghe, and L. Michaux. "Genetics of Chronic Lymphocytic Leukemia: Practical Aspects and Prognostic Significance." In Chronic Lymphocytic Leukemia. InTech, 2012. http://dx.doi.org/10.5772/29336.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

"Chronic Lymphocytic Leukemia: Epidemiological, Familial, and Genetic Aspects." In Chronic Lymphoid Leukemias, 53–82. CRC Press, 2001. http://dx.doi.org/10.1201/9781420002287-10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

"Psychological Aspects of Chronic Lymphoid Leukemia." In Chronic Lymphoid Leukemias, 617–32. CRC Press, 2001. http://dx.doi.org/10.1201/9781420002287-34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Psychological aspects of Lymphocytic leukemia"

1

Hingley, Sally. Psycho-social Aspects of Acute Lymphocytic Leukemia in Children. Portland State University Library, January 2000. http://dx.doi.org/10.15760/etd.1616.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!